Проект Андре Кронье привлек $200 млн на DeFi-биржу

cryptonews.ru2025-05-29 tarihinde yayınlandı2025-09-30 tarihinde güncellendi

Flying Tulip от DeFi-разработчика Андре Кронье привлек $200 млн в ходе посевного раунда. Команда создаст биржу, которая объединит спотовую и деривативную торговлю, лендинг, стейблкоины и страхование в одной системе.

https://t.co/bmLOA6fzzO pic.twitter.com/y36lg7QM0P

— Andre Cronje (@AndreCronjeTech) September 29, 2025

Раунд прошел в формате SAFT при оценке проекта в $1 млрд (FDV). Среди инвесторов — Brevan Howard Digital, CoinFund, DWF Labs, FalconX, Hypersphere и другие.

Проект планирует привлечь еще до $800 млн через публичную продажу токенов FT по той же оценке. Сейл пройдет на собственной платформе Flying Tulip.

«Право выкупа» для инвесторов

Ключевая особенность раунда — «ончейн-право выкупа». Инвесторы в любой момент могут сжечь FT и вернуть свой первоначальный капитал в том активе, который вносили, например Ethereum. Кронье заявил, что эта модель защищает инвесторов от убытков, сохраняя при этом «неограниченный потенциал роста».

Привлеченные средства не будут тратиться напрямую. Команда планирует разместить их в DeFi-протоколах вроде Aave и Ethena. Ожидаемая доходность в 4% годовых сможет генерировать около $40 млн в год. Эти деньги пойдут на развитие проекта, стимулирование пользователей и обратный выкуп токенов.

По словам Кронье, на создание такой модели его подтолкнул прошлый опыт. Давление из-за цены токена заставляет принимать краткосрочные решения в ущерб протоколу. Механизм выкупа снижает этот стресс.

Участники команды не получат первоначальной аллокации токенов. Их вознаграждение будет поступать от выкупа активов с открытого рынка, финансируемого за счет доходов протокола.

Биржа «полного цикла»

По словам Кронье, Flying Tulip не просто DEX, а «пересборка с нуля» всех ключевых DeFi-сервисов.

После запуска биржа будет работать в сетях Ethereum, Avalanche, BNB Chain, Sonic и Solana. Изначально платформу развернут в Sonic, где предложат торговлю с нулевыми комиссиями. Точная дата запуска пока неизвестна.

Напомним, в августе Sonic Labs одобрила план по выходу на рынок капитала США.

İlgili Okumalar

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit20 dk önce

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit20 dk önce

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit21 dk önce

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit21 dk önce

İşlemler

Spot
活动图片